Advertisement
Australia markets close in 30 minutes
  • ALL ORDS

    8,058.60
    +83.50 (+1.05%)
     
  • ASX 200

    7,821.20
    +87.50 (+1.13%)
     
  • AUD/USD

    0.6665
    +0.0006 (+0.09%)
     
  • OIL

    81.74
    +0.11 (+0.13%)
     
  • GOLD

    2,341.80
    -2.60 (-0.11%)
     
  • Bitcoin AUD

    91,656.58
    -1,948.29 (-2.08%)
     
  • CMC Crypto 200

    1,273.98
    -35.74 (-2.73%)
     
  • AUD/EUR

    0.6203
    +0.0005 (+0.08%)
     
  • AUD/NZD

    1.0881
    +0.0014 (+0.13%)
     
  • NZX 50

    11,716.44
    +88.58 (+0.76%)
     
  • NASDAQ

    19,474.62
    -225.81 (-1.15%)
     
  • FTSE

    8,281.55
    +43.83 (+0.53%)
     
  • Dow Jones

    39,411.21
    +260.88 (+0.67%)
     
  • DAX

    18,325.58
    +162.06 (+0.89%)
     
  • Hang Seng

    18,133.87
    +106.16 (+0.59%)
     
  • NIKKEI 225

    39,102.98
    +298.33 (+0.77%)
     

Amneal to Participate at Upcoming Investor Conference

BRIDGEWATER, N.J., May 22, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024.

Chirag will present at 1:30 PM EST. A live webcast of the presentation will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 generic and specialty pharmaceuticals, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522763089/en/

Contacts

Investor Contact:
Anthony DiMeo
VP, Investor Relations & Media
anthony.dimeo@amneal.com